LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.

Mutations in leucine-rich repeat kinase 2 (LRRK2) lead to late-onset, autosomal dominant Parkinson's disease, characterized by the degeneration of dopamine neurons of the substantia nigra pars compacta, a deficit in dopamine neurotransmission and the development of motor and non-motor symptoms....

Full description

Bibliographic Details
Main Authors: Sloan, M, Alegre-Abarrategui, J, Potgieter, D, Kaufmann, A, Exley, R, Deltheil, T, Threlfell, S, Connor-Robson, N, Brimblecombe, K, Wallings, R, Cioroch, M, Bannerman, D, Bolam, J, Magill, P, Cragg, S, Dodson, P, Wade-Martins, R
Format: Journal article
Language:English
Published: Oxford University Press 2016
_version_ 1797089853668589568
author Sloan, M
Alegre-Abarrategui, J
Potgieter, D
Kaufmann, A
Exley, R
Deltheil, T
Threlfell, S
Connor-Robson, N
Brimblecombe, K
Wallings, R
Cioroch, M
Bannerman, D
Bolam, J
Magill, P
Cragg, S
Dodson, P
Wade-Martins, R
author_facet Sloan, M
Alegre-Abarrategui, J
Potgieter, D
Kaufmann, A
Exley, R
Deltheil, T
Threlfell, S
Connor-Robson, N
Brimblecombe, K
Wallings, R
Cioroch, M
Bannerman, D
Bolam, J
Magill, P
Cragg, S
Dodson, P
Wade-Martins, R
author_sort Sloan, M
collection OXFORD
description Mutations in leucine-rich repeat kinase 2 (LRRK2) lead to late-onset, autosomal dominant Parkinson's disease, characterized by the degeneration of dopamine neurons of the substantia nigra pars compacta, a deficit in dopamine neurotransmission and the development of motor and non-motor symptoms. The most prevalent Parkinson's disease LRRK2 mutations are located in the kinase (G2019S) and GTPase (R1441C) encoding domains of LRRK2. To better understand the sequence of events that lead to progressive neurophysiological deficits in vulnerable neurons and circuits in Parkinson's disease, we have generated LRRK2 bacterial artificial chromosome transgenic rats expressing either G2019S or R1441C mutant, or wild-type LRRK2, from the complete human LRRK2 genomic locus, including endogenous promoter and regulatory regions. Aged (18-21 months) G2019S and R1441C mutant transgenic rats exhibit L-DOPA-responsive motor dysfunction, impaired striatal dopamine release as determined by fast-scan cyclic voltammetry, and cognitive deficits. In addition, in vivo recordings of identified substantia nigra pars compacta dopamine neurons in R1441C LRRK2 transgenic rats reveal an age-dependent reduction in burst firing, which likely results in further reductions to striatal dopamine release. These alterations to dopamine circuit function occur in the absence of neurodegeneration or abnormal protein accumulation within the substantia nigra pars compacta, suggesting that nigrostriatal dopamine dysfunction precedes detectable protein aggregation and cell death in the development of Parkinson's disease. In conclusion, our longitudinal deep-phenotyping provides novel insights into how the genetic burden arising from human mutant LRRK2 manifests as early pathophysiological changes to dopamine circuit function and highlights a potential model for testing Parkinson's therapeutics.
first_indexed 2024-03-07T03:10:04Z
format Journal article
id oxford-uuid:b3e2a782-5ac7-4fec-ab92-12a50b1578da
institution University of Oxford
language English
last_indexed 2024-03-07T03:10:04Z
publishDate 2016
publisher Oxford University Press
record_format dspace
spelling oxford-uuid:b3e2a782-5ac7-4fec-ab92-12a50b1578da2022-03-27T04:22:22ZLRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b3e2a782-5ac7-4fec-ab92-12a50b1578daEnglishSymplectic Elements at OxfordOxford University Press2016Sloan, MAlegre-Abarrategui, JPotgieter, DKaufmann, AExley, RDeltheil, TThrelfell, SConnor-Robson, NBrimblecombe, KWallings, RCioroch, MBannerman, DBolam, JMagill, PCragg, SDodson, PWade-Martins, RMutations in leucine-rich repeat kinase 2 (LRRK2) lead to late-onset, autosomal dominant Parkinson's disease, characterized by the degeneration of dopamine neurons of the substantia nigra pars compacta, a deficit in dopamine neurotransmission and the development of motor and non-motor symptoms. The most prevalent Parkinson's disease LRRK2 mutations are located in the kinase (G2019S) and GTPase (R1441C) encoding domains of LRRK2. To better understand the sequence of events that lead to progressive neurophysiological deficits in vulnerable neurons and circuits in Parkinson's disease, we have generated LRRK2 bacterial artificial chromosome transgenic rats expressing either G2019S or R1441C mutant, or wild-type LRRK2, from the complete human LRRK2 genomic locus, including endogenous promoter and regulatory regions. Aged (18-21 months) G2019S and R1441C mutant transgenic rats exhibit L-DOPA-responsive motor dysfunction, impaired striatal dopamine release as determined by fast-scan cyclic voltammetry, and cognitive deficits. In addition, in vivo recordings of identified substantia nigra pars compacta dopamine neurons in R1441C LRRK2 transgenic rats reveal an age-dependent reduction in burst firing, which likely results in further reductions to striatal dopamine release. These alterations to dopamine circuit function occur in the absence of neurodegeneration or abnormal protein accumulation within the substantia nigra pars compacta, suggesting that nigrostriatal dopamine dysfunction precedes detectable protein aggregation and cell death in the development of Parkinson's disease. In conclusion, our longitudinal deep-phenotyping provides novel insights into how the genetic burden arising from human mutant LRRK2 manifests as early pathophysiological changes to dopamine circuit function and highlights a potential model for testing Parkinson's therapeutics.
spellingShingle Sloan, M
Alegre-Abarrategui, J
Potgieter, D
Kaufmann, A
Exley, R
Deltheil, T
Threlfell, S
Connor-Robson, N
Brimblecombe, K
Wallings, R
Cioroch, M
Bannerman, D
Bolam, J
Magill, P
Cragg, S
Dodson, P
Wade-Martins, R
LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
title LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
title_full LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
title_fullStr LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
title_full_unstemmed LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
title_short LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
title_sort lrrk2 bac transgenic rats develop progressive l dopa responsive motor impairment and deficits in dopamine circuit function
work_keys_str_mv AT sloanm lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction
AT alegreabarrateguij lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction
AT potgieterd lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction
AT kaufmanna lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction
AT exleyr lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction
AT deltheilt lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction
AT threlfells lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction
AT connorrobsonn lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction
AT brimblecombek lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction
AT wallingsr lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction
AT ciorochm lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction
AT bannermand lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction
AT bolamj lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction
AT magillp lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction
AT craggs lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction
AT dodsonp lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction
AT wademartinsr lrrk2bactransgenicratsdevelopprogressiveldoparesponsivemotorimpairmentanddeficitsindopaminecircuitfunction